title: [Graves' disease. Clinical features and treatment results].
abstract: In the last years the diagnosis of Grave's disease has become easier and accelerated due to new laboratory and instrumental tests. The therapeutic possibilities improved also by using antithyroidal drugs, surgery and radioiodine application subsequently. In a retrospective study 278 outpatients with Graves disease, treated and controlled by our centre for thyroid diseases in 1992-1999, were investigated to evaluate the initial and leading subjective symptoms which led the patients to seek medical help ("guide symptoms"). These obtained guide symptoms were compared with the objective "clinical signs" observed at the beginning of the disease. Weight loss turned out to be the most frequent (26%) guide symptom, whereas tachycardia (> 90 beats/min) and moist skin were the most frequently observed clinical signs (71 and 61% respectively). The beginning of therapy, dosage of drugs, length of application and results of treatment are critically evaluated, with special emphasis on the rate and time of remission, on the frequency of recurrences and on the success of additional treatments such as surgery and/or radioiodine application. Pharmacological treatment alone induced a persistent remission (at least 6 months of euthyroidism) in 156 patients (in 113 after the first and in 43 after the 2nd drug trial). Surgery was successful in 46, radioiodine application in 40 patients. The sequential use of drug therapy, surgery and radioiodine as it is performed in our institution leads to a permanent remission in 242 of 278 (= 87%) patients.
authors.affiliation: II. Medizinische Abteilung, Regionalkrankenhaus Bozen, Lorenz-Böhler-Strasse 5, I-39100 Bozen, Italien.
authors.forename: C
authors.initials: C
authors.lastname: Crivellaro
authors.forename: R
authors.initials: R
authors.lastname: Oberhofer
authors.forename: K
authors.initials: K
authors.lastname: Leimgruber
authors.forename: H
authors.initials: H
authors.lastname: Amor
mesh_terms: D013956:Antithyroid Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006111:Graves Disease / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D013546:Sweating; D013610:Tachycardia; D013965:Thyroidectomy; D013974:Thyroxine / Q000097:blood; D014202:Tremor; D014284:Triiodothyronine / Q000097:blood; D015431:Weight Loss
chemical_list: D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013974:Thyroxine